Ardelyx, Inc. (ARDX:NASDAQ) closed at $3.09 on November 13, 2026, down 0.96% on the day. The stock trades 63.2% below its 52-week high of $8.40 and 10.4% above its 52-week low of $2.80. Over the past year, it lost 47.3%. Ardelyx, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ARDX closed higher on 103 days (41%). Its best day was January 8, 2026 (+20.07%) and its worst was August 7, 2026 (-17.86%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 2 times.
Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Find more stocks like ARDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.